NCT05025631 (DOFEMCRC) is a Phase 2 clinical trial of Fruquintinib in Colorectal Cancer, sponsored by Zhen-Yu Ding.

Who is sponsoring NCT05025631?

NCT05025631 is sponsored by Zhen-Yu Ding.

What drugs are being tested in NCT05025631?

Interventions in NCT05025631: Fruquintinib.

What condition does NCT05025631 study?

NCT05025631 studies Colorectal Cancer.

Is NCT05025631 still recruiting?

NCT05025631 is currently completed. Last updated 28 April 2023.

Last reviewed 2023-04-28 · How we verify

NCT05025631: DOFEMCRC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

Completed Phase 2 Last updated 28 April 2023

What this trial tests

Phase 2 trial testing Fruquintinib in Colorectal Cancer in 29 participants. Completed in 30 October 2022.

Timeline

6 November 2020

Primary endpoint
30 October 2022

30 October 2022

Quick facts

Lead sponsor	Zhen-Yu Ding
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	6 November 2020
Primary completion	30 October 2022
Estimated completion	30 October 2022
Sites	1 location across China

Drugs / interventions tested

Fruquintinib — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Zhen-Yu Ding — full company profile →

Who can join

65 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase II study on dose optimization of fruquintinib in elderly metastatic colorectal cancer patients refractory to standard treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S, Zhang S, Zhou N, Cai X, et al · · 2023 · cited 9× · PMID 38063405 · DOI 10.1002/cam4.6786
Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview.
Xie Y, Tang S, Qin Z, Yang C. · · 2025 · cited 3× · PMID 40006092 · DOI 10.3390/ph18020280

Verify or expand the search:

Other trials of Fruquintinib

Trials testing the same drug.

NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07124858 — Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metast · NA · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07235293 — A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorecta · Phase 2 · recruiting

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Zhen-Yu Ding trials

Trials by the same sponsor.

NCT06329908 — DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05025631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhen-Yu Ding
Last refreshed: 28 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing